↓ Skip to main content

Dove Medical Press

Article Metrics

Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex

Overview of attention for article published in Biologics: Targets & Therapy, October 2013
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
71 Mendeley
Title
Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex
Published in
Biologics: Targets & Therapy, October 2013
DOI 10.2147/btt.s25095
Pubmed ID
Authors

David Franz

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder caused by inactivating mutations in either the TSC1 or TSC2 genes. It is characterized by the development of multiple, benign tumors in several organs throughout the body. Lesions occur in the brain, kidneys, heart, liver, lungs, and skin and result in seizures and epilepsy, mental retardation, autism, and renal and pulmonary organ system dysfunction, as well as other complications. Elucidation of the molecular pathways and etiological factors responsible for causing TSC has led to a paradigm shift in the management and treatment of the disease. TSC1 or TSC2 mutations lead to constitutive upregulation of the mammalian target of rapamycin pathway, which affects many cellular processes involved in tumor growth. By targeting mammalian target of rapamycin with everolimus, an orally active rapamycin derivative, clinically meaningful and statistically significant reductions in tumor burden have been achieved for the main brain (subependymal giant cell astrocytoma) and renal manifestations (angiomyolipoma) associated with TSC. This review provides an overview of TSC, everolimus, and the clinical trials that led to its approval for the treatment of TSC-associated subependymal giant cell astrocytoma and renal angiomyolipoma.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Netherlands 1 1%
United States 1 1%
Brazil 1 1%
Unknown 67 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 21%
Other 11 15%
Student > Master 7 10%
Student > Postgraduate 6 8%
Student > Bachelor 5 7%
Other 17 24%
Unknown 10 14%
Readers by discipline Count As %
Medicine and Dentistry 31 44%
Neuroscience 8 11%
Agricultural and Biological Sciences 7 10%
Biochemistry, Genetics and Molecular Biology 3 4%
Psychology 2 3%
Other 9 13%
Unknown 11 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2013.
All research outputs
#3,563,006
of 4,507,509 outputs
Outputs from Biologics: Targets & Therapy
#81
of 114 outputs
Outputs of similar age
#80,585
of 101,299 outputs
Outputs of similar age from Biologics: Targets & Therapy
#4
of 8 outputs
Altmetric has tracked 4,507,509 research outputs across all sources so far. This one is in the 3rd percentile – i.e., 3% of other outputs scored the same or lower than it.
So far Altmetric has tracked 114 research outputs from this source. They receive a mean Attention Score of 1.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,299 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.